Clinical trials: Hepatitis E
Hepatitis B, Chronic
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV) activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with chronic hepatitis B infection.
- Trial name
- NCT00034359
- Testing
- ACH-126,443, Lamivudine
- Where
- 3 sites in Bulgaria, Federal Republic of Yugoslavia
- Volunteers
- 79 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis B, Chronic
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels.
- Trial name
- NCT04129554
- Testing
- JNJ-73763989, JNJ-56136379, Entecavir (ETV) monohydrate
- Where
- 41 sites in Belgium, France and 5 more
- Volunteers
- 130 people
- Sponsor
- Janssen Sciences Ireland UC
Hepatitis B
Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)
To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.
- Trial name
- NCT00412750
- Testing
- Telbivudine (LdT), peginterferon alpha-2a
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Novartis
Chronic Hepatitis B
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.
- Trial name
- NCT02452528
- Testing
- ARC-520, Entecavir, Tenofovir
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis B, Chronic
A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment
The purpose of this study is to assess the incidence of participants who reach hepatitis B surface antigen (HBsAg) seroclearance after discontinuing nucleos(t)ide analog (NA) therapy in participants with HBsAg less than or equal…
- Trial name
- SALMONS (NCT05550519)
- Testing
- Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
HBeAg-positive Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940471
- Testing
- TAF, TDF
- Where
- 160 sites in United States, Australia and 17 more
- Volunteers
- 875 people
- Sponsor
- Gilead Sciences
Hepatitis E
Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above
The purpose of this study is to evaluate the safety and non-inferior immunogenicity of thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli) compared with licensed Recombinant Hepatitis E Vaccine (Escherichia Coli)…
- Trial name
- NCT06564116
- Testing
- Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli), Recombinant Hepatitis E Vaccine (Escherichia Coli)
- Where
- China
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Hepatitis B, Chronic
PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)
The purpose of this study is to determine the efficacy and safety of two dosages of PegIntron for treating hepatitis B e antigen (HBeAg) positive chronic hepatitis B compared with the approved dosage, which is PegIntron 1.0…
- Trial name
- NCT00536263
- Testing
- pegylated interferon alpha-2b
- Volunteers
- 671 people
- Sponsor
- Merck Sharp & Dohme LLC
HBeAg-negative Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940341
- Testing
- TAF, TDF
- Where
- 105 sites in United States, Australia and 15 more
- Volunteers
- 426 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
This study is to evaluate the antiviral efficacy of add-on adefovir to telbivudine in non-responders to telbivudine monotherapy after 24 and 36 initial weeks.
- Trial name
- NCT00537537
- Testing
- Telbivudine
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).
- Trial name
- ASPIRE-202 (NCT07654283)
- Testing
- AHB-137
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 70 people
- Sponsor
- AusperBio Therapeutics Inc.